Figure S1. Identification of  $T-\alpha/\beta/\omega$ MCA by fragmentation profiles and RTs. (A) TIC chromatogram of m/z 514.284 in the mouse serum sample. (B) MS/MS spectra of the peak with a RT of 9.283 in the mouse serum in part A. (C) TIC chromatogram of authentic T- $\alpha$ MCA when fragmentation was performed at m/z 514.284. (D) MS/MS spectra of the peak, with a RT of 9.25 in panel C. (E) TIC chromatogram of authentic T- $\beta$ MCA when the fragmentation was performed at m/z 514.284. (F) MS/MS spectra of the peak, with a RT of 9.32 in part E. (G) TIC chromatogram of authentic T- $\omega$ MCA when the fragmentation was performed at m/z 514.2796. (H) MS/MS spectra of the peak, with a RT of 9.21 in part G. T- $\alpha$ MCA, tauro- $\alpha$ -muricholic acid; T- $\beta$ MCA, tauro- $\beta$ -muricholic acid; T- $\omega$ MCA, tauro- $\alpha$ -muricholic acid; TIC, total ion count; RT, retention time.



Figure S2. Identification of TCDCA by fragmentation profiles and RTs. (A) TIC chromatogram of m/z 498.278 in the mouse serum sample. (B) MS/MS spectra of the peak with a RT of 10.950 in the mouse serum in part A. (C) TIC chromatogram of authentic TCA when the fragmentation was performed at m/z 498.287. (D) MS/MS spectra of the peak, with RT 10.693 in part C. TCDCA, taurochenodeoxycholic acid; TIC, total ion count; RT, retention time.



Figure S3. Identification of TUDCA by fragmentation profiles and RTs. (A) TIC chromatogram of m/z 498.288 in the mouse serum sample. (B) MS/MS spectra of the peak with a RT of 10.02 in the mouse serum in part A. (C) TIC chromatogram of authentic TCA when the fragmentation was performed at m/z 498.287. (D) MS/MS spectra of the peak, with a RT of 10.03 in part C. TUDCA, tauroursodeoxycholic acid; TIC, total ion count; RT, retention time.



Figure S4. Identification of TDCA by fragmentation profiles and RTs. (A) TIC chromatogram of m/z 498.287 in the mouse serum sample. (B) MS/MS spectra of the peak with a RT of 11.16 in the mouse serum in part A. (C) TIC chromatogram of authentic TCA when the fragmentation was performed at m/z 489.287. (D) MS/MS spectra of the peak, with a RT of 11.18 in panel C. TDCA, taurodeoxycholic acid; TIC, total ion count; RT, retention time.



Table SI. Primer sequences used in the reverse transcription-quantitative PCR.

Gene	Primer sequence $(5' \rightarrow 3')$	Product (bp)
Cholesterol 7a-hydroxylase	F: GTCCGGATATTCAAGGATGC	107
	R: GGGAATGCCATTTACTTGGA	
Sterol 12a-hydroxylase	F: GATAGGGGAAGAGAGCCACC	96
	R: TCCTCAGGGTGGTACAGGAG	
Multidrug resistance-related protein 4	F: TTAGATGGGCCTCTGGTTCT	102
	R: GCCCACAATTCCAACCTTT	
Multidrug resistance protein 1a	F: CTCTATTGGACAAGTGCTCACTG	104
	R: CTCCTCGTGCATTGGCGAA	
Organic solute transporter- $\beta$	F: CCAGGACCAGGATGGAATAA	110
	R: AGAGAAAGCTGCAGCCAATG	
Oatp1	F: TAATCGGGCCAACAATCTTC	109
	R: ACTCCCATAATGCCCTTGG	
Oatp2	F: TAGCTGAATGAGAGGGCTGC	103
	R: ACCAAACTCAGCATCCAAGC	
Multidrug resistance protein 2	F: ACGGGCTCTTGACTTACCAC	105
	R: CTACGACCCCACAGAGGGTA	
c-Fos	F: TGGCACTAGAGACGGACAGA	94
	R: TCCTACTACCATTCCCCAGC	
c-Jun	F: GGGACACAGCTTTCACCCTA	104
	R: GAAAAGTAGCCCCCAACCTC	
1110	F: TGTCAAATTCATTCATGGCCT	108
	R: ATCGATTTCTCCCCTGTGAA	
116	F: ACCAGAGGAAATTTTCAATAGC	109
	R: TGATGCACTTGCAGAAAACA	
Tumor necrosis factor a	F: AGGGTCTGGGCCATAGAACT	103
	R: CCACCACGCTCTTCTGTCTAC	
Fibrinogen a chain	F: CAACTCTTGGGCCACGTACT	108
	R: GGGTCACCTGCCTCATCTT	
Fibrinogen $\beta$ chain	F: AGGAGGCTCTTCCTTTCTCC	90
	R: CAAGCTGCCGATGATGACTA	
Suppressor of cytokine signaling 3	F: AACTTGCTGTGGGTGACCAT	136
	R: CGGCTACCACATCCAAGGAA	
18S ribosomal RNA	F: ATTGGAGCTGGAATTACCGC	102
	R: AAGGCCGGAGATTTCGCT	

*Il*, interleukin; *Oatp*, organic anion transporting polypeptide; F, forward; R, reverse.